Trebananib

Summary

Trebananib (CHEMBL2108568) is a phase-3 clinical-stage unknown; indicated across 17 conditions including peritoneal neoplasm and fallopian tube neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 17 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108568
Name	Trebananib
Type	Unknown
Max phase	3

Also known as: AMG 386, AMG-386, Trebananib, TREBANANIB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

17 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peritoneal neoplasm	3	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	3	MONDO:0021092	MONDO:0002158
ovarian cancer	3	MONDO:0008170	MONDO:0008170
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
oligodendroglioma	2	MONDO:0016695	EFO:0000632
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
angiosarcoma	2	MONDO:0016982	EFO:0003968
gliosarcoma	2	MONDO:0016681	EFO:1001465
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
breast neoplasm	2	MONDO:0021100	MONDO:0007254
glioblastoma	2	MONDO:0018177	EFO:0000519
brain neoplasm	2	MONDO:0021211	EFO:0003833
soft tissue sarcoma	2	MONDO:0018078	EFO:1001968
neoplasm	1	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00853372	PHASE2	COMPLETED	AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
NCT01210222	PHASE2	COMPLETED	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01609790	PHASE2	COMPLETED	Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
NCT01623869	PHASE2	COMPLETED	Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
NCT01664182	PHASE2	COMPLETED	Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
NCT01538095	PHASE1	COMPLETED	Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
NCT01548482	PHASE1	COMPLETED	Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01555268	PHASE1	COMPLETED	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
NCT02525536	PHASE1	COMPLETED	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors
NCT03239145	PHASE1	COMPLETED	Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).